Table 1.
Baseline clinical characteristics of all patients.
| Variable | N | % |
|---|---|---|
| Menopausal status | ||
| Pre-menopausal | 27 | 62.8% |
| Post-menopausal | 16 | 37.2% |
| Staging | ||
| II-b | 16 | 37.2% |
| III | 27 | 62.8% |
| Histologic type | ||
| Invasive ductal carcinoma | 33 | 76.7% |
| Other types | 10 | 23.3% |
| ER status | ||
| Negative | 22 | 51.2% |
| Positive* | 21 | 48.8% |
| PR status | ||
| Negative | 27 | 62.8% |
| Positive* | 16 | 37.2% |
| HER-2 status | ||
| Negative | 25 | 58.1% |
| Positive* | 18 | 41.9% |
| Ki-67 index | ||
| Negative | 10 | 22.3% |
| Positive* | 33 | 76.7% |
| Surgical types | ||
| Breast conservation | 2 | 4.7% |
| mastectomy | 41 | 95.3% |
| Neoadjuvant Chemotherapy regimen | ||
| EC or FEC | 7 | 16.2% |
| CET or AC-T or PD +/-H | 36 | 83.8% |
*ER, PR Positive defined as “IHC positive cells ≥10%”; HER-2, Positive defined as “IHC 2+ OR Fish HER-2 gene amplified”; Ki-67, index positive defined as “IHC positive cells ≥30%”.